Clearmind Medicine Inc.
corporate_fare Company Profile
Clearmind Medicine Inc. (NASDAQ:CMND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 76 items for CMND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for CMND spans 6-K.
Recent high-impact activity:
- Clearmind Doses First Alcohol Use Disorder Patients in CMND-100 Trial
- Clearmind Closes $2.5M Charging Robotics Acquisition, Adds $1.5M Loan
- Yale IRB Approval Clears Path for Parts B and C of Clearmind Medicine's CMND-100 Trial
- Yale IRB Greenlights Patient Recruitment for Clearmind's CMND-100 Phase I/II Trial
- Clearmind Signs Definitive $2.5M Deal for 51% of EV Wireless Charging Firm
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for CMND, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.
Going Concern Warning Issued · Significant Capital Raise and Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
CMND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.